CME Group price target lowered to $280 from $285 at UBS

UBS analyst Alex Kramm lowered the firm’s price target on CME Group (CME) to $280 from $285 and keeps a Neutral rating on the shares. The firm sees “no shortage of initiatives” at CME, but argues that the near-term volume picture “remains tough.”